Teva converts Copaxone users

Share this article:

Generic Copaxone may not gut Teva's earnings if the drugmaker continues to convert users to its latest formulation. “'We may have failed to understand just how comprehensive Teva's patient outreach system has been,” Cowen analyst Ken Cacciatore tells Bloomberg Businessweek.

Businessweek reports that Teva has managed to migrate 8.7% of its 20mg prescriptions to the new, three-times-a week 40mg version of the MS drug as of February 28.

Teva anticipated that generic Copaxone could inflict serious damage on its outlook, so much so that its 2014 guidance included life-with and life-without generic Copaxone numbers.

Teva said in December that every month without generic Copaxone enriches it by $78 million. Bloomberg reported at the time that the generic could push Teva into its first sales drop in two decades.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.